We are live on ! Find out more
NRSN icon

NeuroSense Therapeutics
NRSN

4 hedge funds and large institutions have $132K invested in NeuroSense Therapeutics in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.23% less ownership

Funds ownership: 1.86% → 0.63% (-1.2%)

43% less funds holding

Funds holding: 7 → 4 (-3)

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

82% less capital invested

Capital invested by funds: $733K → $132K (-$601K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
4
Holders Change
-3
Holders Change %
-42.86%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
2
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$111K
2
Carson Wealth (CWM LLC)
Carson Wealth (CWM LLC)
Nebraska
+$2.05K

Top Sellers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
-$261K
2
Citigroup
Citigroup
New York
-$168K
3
Millennium Management
Millennium Management
New York
-$68K
4
Vanguard Personalized Indexing Management
Vanguard Personalized Indexing Management
California
-$47.3K
5
TRCT
Tower Research Capital (TRC)
New York
-$33K

NRSN Hedge Fund Activity: Q3 2022 in Review

4 of the 5,829 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics (NRSN) for Q3 2022, worth a combined $132K — down 82% from $733K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of NRSN and 2 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 0 added.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $111K. The largest seller was Jane Street, exiting entirely with an estimated $261K sold.

  • 4 institutional investors held NeuroSense Therapeutics (NRSN) as of Q3 2022, down from 7 in Q2 2022.
  • Funds reported $132K of NeuroSense Therapeutics stock for Q3 2022, down 82% quarter-over-quarter.
  • 2 funds opened new NeuroSense Therapeutics positions in Q3 2022 and 5 closed out, a net change of -3 holders.
  • The largest NeuroSense Therapeutics buyer in Q3 2022 was Renaissance Technologies, an estimated $111K added.
  • The largest NeuroSense Therapeutics seller in Q3 2022 was Jane Street, an estimated $261K sold.

Based on aggregated 13F filings for Q3 2022.